SecBot SecBot
PRESS-RELEASE ·Filed Jul 15, 2026

TLX

Telix Pharmaceuticals Limited
NEUTRAL
Impact 4/10
Horizonmonths Processed4mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight • Neutral

This is an early pipeline milestone with no near-term revenue or regulatory catalyst. Monitor for interim data readouts from OPTIMAL-e and the ProstACT Global Phase 3 trial for TLX591-Tx, which are more material catalysts.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$10.83
T+0 close · Jul 15, 2026 · via day close
Latest settled
+3.51%
T+60 · $11.21
Vs SPY
−0.20%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 16 $10.83entry
  2. T+1 · 4mo ago −3.42%α −2.43% · $10.46
  3. T+5 · 4mo ago −2.95%α −1.28% · $10.51
  4. T+20 · 3mo ago +13.85%α +10.23% · $12.33
  5. T+60 · 6w ago +3.51%α −0.20% · $11.21
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Telix Pharmaceuticals announced first patient dosing in the Phase 2 OPTIMAL-e trial evaluating TLX597-Tx for metastatic hormone-sensitive prostate cancer. This is an early-stage clinical milestone with no financial data or regulatory decision, representing a routine pipeline update for a commercial-stage radiopharmaceutical company.

Key Facts

  • First patients dosed in Phase 2 OPTIMAL-e trial of TLX597-Tx for mHSPC at St Vincent's Hospital Sydney
  • OPTIMAL-e is a single-arm, open-label pilot study evaluating adaptive-dosed TLX597-Tx with ADT and ARPI
  • TLX597-Tx has not received marketing authorization in any jurisdiction
  • TLX597-Tx is a next-generation PSMA-targeting small molecule radioligand therapy candidate
  • Prior OPTIMAL-PSMA study showed favorable biodistribution and dosimetry profile

Financial Impact

No financial figures disclosed; early-stage clinical trial with no revenue or cost impact reported

Risk Factors

  • TLX597-Tx is unapproved and may fail to demonstrate efficacy or safety in the trial
  • Adaptive dosing strategy is novel and may not yield superior outcomes vs standard of care
  • Competition from approved PSMA-targeted therapies (e.g., Pluvicto) in earlier treatment settings

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3328129

Track record

27 reports on TLX

Performance horizon

10 of 21 bullish or bearish reports moved the stock their way by T+1. Best: +29.26% at T+20 after the Jun 1, 2026 report. 19 of 21 went positive at some point.

Filters
  1. Oct 29, 202618d ago 6-K Neutral 5/10 Entry $9.10 to $9.05 Now $8.92 −1.98% ▼ −0.55% −0.07% vs SPY
  2. Oct 20, 202627d ago 6-K Neutral 4/10 No price data
  3. Oct 20, 202627d ago Press Release Bullish 6/10 Entry $10.03 to $9.54 Now $8.92 −11.07% ▼ −4.89% −3.70% vs SPY
  4. Sep 29, 20266w ago 6-K Bullish 6/10 Entry $10.97 to $10.72 Now $8.92 −18.69% ▼ −2.28% −2.46% vs SPY
  5. Sep 21, 20268w ago 6-K Bullish 7/10 Entry $11.31 to $11.95 Now $8.92 −21.13% ▲ +5.66% +5.67% vs SPY
  6. Sep 20, 20268w ago Press Release Bullish 7/10 Entry $11.31 to $11.95 Now $8.92 −21.13% ▲ +5.66% +5.67% vs SPY
  7. Sep 14, 20269w ago 6-K Bullish 8/10 Entry $12.83 to $11.83 Now $8.92 −30.48% ▼ −7.79% −7.35% vs SPY
  8. Sep 14, 20269w ago Press Release Bullish 8/10 Entry $11.78 to $12.83 Now $8.92 −24.28% ▲ +8.91% +9.37% vs SPY
  9. Sep 1, 202610w ago 6-K Bullish 7/10 Entry $11.45 to $11.74 Now $8.92 −22.10% ▲ +2.53% +1.49% vs SPY
  10. Sep 1, 202610w ago Press Release Bullish 6/10 Entry $11.45 to $11.74 Now $8.92 −22.10% ▲ +2.53% +1.49% vs SPY
Showing 10 of 27

US Market Status

Market Closed · Opens Wed (9h 57m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 15, 2026